2023 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ãá°è¿¬¼ö°Á : 2023-05-20
±³À°ÀÏÀÚ : 2023-05-20
±³À°Àå¼Ò : ¼¿ï´ëÇб³ ¾Ï¿¬±¸¼Ò ÀÌ°ÇÈñȦ
±³À°ÁÖÁ¦ : 2023 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ãá°è¿¬¼ö°ÁÂ
ÁÖÃÖ±â°ü : ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ : kspho@kams.or.kr
±³À°Á¾·ù : ¼Ò¾Æû¼Ò³â°ú
Âü¼®¿¹»óÀÎ : 80¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í ÇöÀåµî·Ï 60000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05¿ù 20ÀÏ ÀÌ°ÇÈñȦ 10:30~11:00 Bone marrow failure syndrome ±è¼º±¸(°¡Å縯ÀÇ´ë )
±³À°½Ã°£ 05¿ù 20ÀÏ ÀÌ°ÇÈñȦ 11:00~11:30 Non Hodgkin's lymphoma and Hodgkin's disease ÁÖÈñ¿µ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 05¿ù 20ÀÏ ÀÌ°ÇÈñȦ 11:30~12:00 Disease spectrum: macrophage activating syndrome, hemophagocytic lymphohistiocytosis and cytokine releasing syndrome °¼ºÇÑ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05¿ù 20ÀÏ ÀÌ°ÇÈñȦ 13:00~13:30 systematic approach to the WBC disorders À±È¸¼ö(°æÈñÀÇ´ë)
±³À°½Ã°£ 05¿ù 20ÀÏ ÀÌ°ÇÈñȦ 13:30~14:00 systematic approach to the hemolytic anemia ÀÌÀçÈñ(ÃæºÏÀÇ´ë )
±³À°½Ã°£ 05¿ù 20ÀÏ ÀÌ°ÇÈñȦ 14:00~14:30 systematic approach to the platelet disorders À̳ªÈñ(Â÷ÀÇ°úÇдë)
±³À°½Ã°£ 05¿ù 20ÀÏ ÀÌ°ÇÈñȦ 14:40~15:20 °íÀ§Ç豺 ½Å°æ¸ð¼¼Æ÷Á¾ÀÇ Ä¡·á ¼º±â¿õ(¼º±Õ°üÀÇ´ë )
±³À°½Ã°£ 05¿ù 20ÀÏ ÀÌ°ÇÈñȦ 15:30~16:00 Current standard treatment for rhabdomyosarcoma and other soft tissue sarcomas ¹Ú¹Ì¸²(±¹¸³¾Ï¼¾ÅÍ )
±³À°½Ã°£ 05¿ù 20ÀÏ ÀÌ°ÇÈñȦ 16:00~16:30 Current standard treatment for germ cell tumor °ø¼¶±è(°í½ÅÀÇ´ë )
±³À°½Ã°£ 05¿ù 20ÀÏ ÀÌ°ÇÈñȦ 16:30~17:00 Current standard treatment for osteosarcoma ÀÌÀº»ó(°í·ÁÀÇ´ë )
±³À°½Ã°£ 05¿ù 20ÀÏ ÀÌ°ÇÈñȦ 17:00~17:30 Current standard treatment for ewing sarcoma family of tumors ¼Áø°æ(¿øÀڷº´¿ø)